BPC-157 (Pentadecapeptide)

BPC-157 vs TB-500 Compared

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library2 min readLast reviewed 2026-08-234 cited sources

The short answer

BPC-157 is a 15-residue peptide from a gastric juice protein at 1419.5 Da, with registered clinical trials including a recruiting Phase 2. TB-500 is a 7-residue fragment of thymosin beta-4's actin-binding motif at 889.0 Da, whose most-cited findings largely used the full protein.

Key facts

BPC-157
15 residues, 1419.5 Da
TB-500
7 residues, 889.0 Da
BPC-157 origin
Gastric juice protein sequence
TB-500 origin
Thymosin beta-4 residues 17-23
BPC-157 mechanism
Reported multi-pathway
TB-500 mechanism
Actin sequestration
BPC-157 clinical
Phase 2 recruiting (NCT07437547)
TB-500 clinical
No established programme

Different molecules entirely

They share nothing structurally. BPC-157 is fifteen residues, proline- and glycine-rich, derived from a gastric juice protein. TB-500 is seven residues, an internal motif of a 43-residue actin-binding protein with an acetylated N-terminus. Different sequences, different sizes, different parents.

Different mechanistic pictures

TB-500's mechanism is comparatively well defined: its parent is the principal G-actin sequestering protein in many cell types, and the fragment carries the motif associated with that. BPC-157's reported mechanism is multi-pathway and correspondingly less sharp (angiogenic signalling, growth-factor interactions and effects across several systems), without a single defining molecular action.

Research material referenced

BPC-157 5mg, third-party HPLC tested

Buy BPC-157 · £16.95

The evidential difference that actually separates them

This is the most useful distinction and it is rarely made. BPC-157 has entered registered clinical development as PL-14736 for inflammatory bowel disease, with a Phase 1 study in 42 healthy volunteers and a randomised placebo-controlled Phase 2 recruiting now with 120 participants. TB-500 has no comparable programme. Meanwhile much of TB-500's most-cited literature used full-length thymosin beta-4 rather than the fragment sold under the name.

What they have in common

Both are preclinically characterised largely in rodent models. Both are associated with repair and healing language in commercial writing that outruns what the studies measured. Both are WADA-relevant. And both are supplied for laboratory research with no marketing authorisation anywhere.

On combining them

They appear together in commercial blends, and the rationale offered is mechanistic non-overlap. Whether combination has been studied as such is a separate question, addressed in the TB-500 category. The short answer is that a rationale is not a result, and the factorial design that would test it does not exist.

Quick reference

BPC-157TB-500
Residues157
Molecular weight1419.5 Da889.0 Da
OriginGastric juice proteinThymosin β4, residues 17-23
CAS137525-51-0None (parent: 77591-33-4)
PubChem CID994195762707662
MechanismMulti-pathway, less definedActin sequestration
Registered trialsPhase 1 and Phase 2None established

Frequently asked questions

Which has better evidence?

BPC-157, on the basis that it has entered registered clinical development including a currently recruiting placebo-controlled Phase 2. Neither has a reported clinical result.

Should they be used together?

That is a separate question from comparing them, covered in the TB-500 category. The combination rationale is mechanistic rather than tested.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More BPC-157 (Pentadecapeptide) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.